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A B S T R A C T
Background: This meta-analytic review is the first to synthesise findings from prospective research on the
long-term course of borderline personality disorder in adult clinical populations.
Methods: Systematic searches were conducted in Medline, PsycINFO, PsycArticles, PubMed and Scopus
within the period 1990-2017. Inclusion criteria were: (1) adult BPD sample diagnosed by a validated,
semi-structured interview; (2) at least two prospective assessments of outcomes; and (3) follow-up
period  5 years. Quality of evidence was rated with the Systematic Assessment of Quality in
Observational Research (SAQOR). Four outcomes were meta-analysed using mixed-effect methods:
remission from BPD diagnosis, completed suicide, depressive symptoms, and functioning. Potential
moderators regarding the natural course and the initial treatment received were studied.
Results: Eleven studies met the inclusion criteria, with 837 participants from nine countries being
followed. Between 50% and 70% of the BPD patients achieved remission in the long-term. Significant
reductions in depression and functional impairment were also found. Mean suicide rate ranged from 2%
to 5%. Younger age was associated with higher likelihood for remission. Being female was correlated with
lower functional improvement. Despite some positive trends, there were no significant associations
between treatment moderators and the long-term outcome.
Conclusions: Findings suggest that the course of BPD is characterised by symptomatic amelioration and a
slight functional improvement in the long-term. Age and gender modulate the long-term prognosis and
should be considered to adapt treatment resources. Further research is required to draw robust
conclusions on the long-term effects of psychotherapeutic interventions.
© 2018 Elsevier Masson SAS. All rights reserved.
Contents lists available at ScienceDirect
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Over the last few decades, there has been growing evidence that
the natural course of borderline personality disorder (BPD) is
characterised by its plasticity, with consecutive periods of remission
and relapse, and shows a trend towards symptomatic amelioration
over time. Despite that, adults with BPD appear to frequently suffer
from poor psychosocial functioning in the long-term [1,2,3]. Bearing
this in mind, Paris suggested that treatment efficacy should be
assessed in terms of their contribution to enhance the natural* Corresponding author at: Department of Clinical Psychology and Psychobiology,
Division of Personality, Assessment and Psychological Treatments, Faculty of
Psychology, University of Barcelona, Spain.
E-mail address: irene.alvareztomas@gmail.com (I. Álvarez-Tomás).
http://dx.doi.org/10.1016/j.eurpsy.2018.10.010
0924-9338/© 2018 Elsevier Masson SAS. All rights reserved.process of the disorder. In this respect, it is noteworthy to study the
impact of psychotherapeutic interventions in patients with BPD in
the long-term, both in the symptomatic and functional domains
[2,3].
Two main prospective studies provided evidence on a wide
range of aspects related to the long-term course of adults with
BPD: the McLean Study of Adult Development (MSAD) and the
Collaborative Longitudinal Personality Study (CLPS) [4,5,6]. Both
research projects demonstrated that it is common for BPD patients
to experience periods of symptomatic remission over time,
reporting high cumulative rates by 10 years (85% 12-month
remission in CLPS; 93% 2-year remission in MSAD) [6]. At 16 years,
the MSAD also reported that 78% of BPD patients had achieved a
long-lasting remission of eight consecutive years [7]. Nevertheless,
the recovery of psychosocial functioning was less consistent than
symptomatic remission, oscillating between a steady functional
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MSAD [6]. Besides, patients with BPD were mostly not able to
achieve normal levels of functioning in the long-term: only 33%
had good functioning after 6 years in MSAD; and just 21% did so
after 10 years in CLPS [8,9].
Apart from the longitudinal research conducted in the US
population, other naturalistic studies were carried out in different
countries (i.e., Spain, Canada, Finland, and Germany) providing
prospective data for a period of five years or more. Findings in these
studies add to the evidence that the course of BPD is characterised by
symptomatic improvement, although remission rates ranged widely
from 31% to 81%, which were informed at different time points of
follow-up [10,11,12,13]. Álvarez-Tomás et al. also reported a slight
improvement of psychosocial functioning in a Spanish sample
followed up at 10 years, although dysfunctional levels of adjustment
were maintained [10]. Moreover, only one third of subjects with BPD,
on average, achieved both symptomatic and functional recovery at a
14-year follow-up in a German study [13].
Further analysis of potential moderators should be required to
take into account variations on the course of BPD among studies. In
this regard, previous longitudinal research pointed out the following
factors as predictors of long-term outcomes: demographic charac-
teristics, childhood experiences, stressful life events, treatment
history, psychopathologic comorbidity, personality traits, and
premorbid psychosocial functioning [14,15,16,17,18].
In addition to naturalistic research, clinical trials of psycho-
therapeutic interventions for BPD have recently shown greater
interest in their long-term outcomes, reporting follow-up data for
five years or more [19,20,21,22,23]. This longitudinal perspective
on efficacy studies underlines the relevance of treatment as a
potential factor of change over time. Nevertheless, findings are
controversial among studies with respect to a differential impact of
specialised therapies in comparison to treatment as usual (TAU) on
diagnostic change and social functioning in the long-term.
Bateman and Fonagy reported significant differences on remission
favouring mentalisation-based treatment (MBT) over TAU (86% vs.
13%), but this effect was not found for other specialised therapies
[19,20,21]. Antonsen et al. reported better outcomes for the social
functioning of a specialised therapy for personality disorders
compared to TAU, in contrast to findings in the Boscot trial
indicating a similar impact of treatment interventions [19,21]. As
far as we are aware, there are no published meta-analyses that
synthesise current evidence on the long-term outcome of
treatment interventions in BPD or that combine these findings
with those from naturalistic prospective research. This may
contribute to the study of long-term treatment effects in the
context of the natural course of the disorder.
Thus, our objective was to conduct a meta-analysis of studies
reporting the prospective results on the long-term course of BPD,
considering both naturalistic and post-treatment follow-up
research. In case of heterogeneity among studies, we were
interested to study the effect of potential moderators related to
the natural course (e.g., age, gender, time of follow-up, psychiatric
comorbidity, and initial level of functioning) and those related to
the treatment interventions received. The following questions
were addressed: (1) What characterises the long-term course of
BPD in adulthood, both in clinical and functional domains? (2) Are
there significant moderators that influence the long-term course of
the disorder?
2. Materials and methods
2.1. Search strategy
Our literature review was guided by the PRISMA standards for
systematic reviews [24]. Bibliographic searches were conducted inMedline, PsycINFO, PsycArticles, PubMed, and Scopus to identify
relevant literature during the period 1990-2017. The searching
strategy was a combination of the following two steps: (1) either
“borderline personality disorder” or “personality disorders” were
used in addition to terms indicating a temporal dimension, i.e.,
“follow-up”, “course”, “longitudinal”, “long-term”, or “mainte-
nance”, in the title or abstract field; (2) the terms “borderline
personality disorder” and either “treatment*”, “therap*”, “psycho-
therap*”, “intervention*”, or “program*” were combined in the title
field and added to similar temporal terms in the abstract field to
identify follow-up clinical studies in BPD samples. We examined
the references of all included articles to identify other relevant
publications and contacted authors to obtain additional informa-
tion. Dissertations and conference papers were also reviewed.
2.2. Selection criteria
Inclusion criteria were: (1) the presence of an adult BPD sample
or subsample in the study, diagnosed by a validated, semi-
structured interview; (2) at least two assessments with repeated
outcome measures related to the course of BPD; and (3) a follow-
up period of 5 years or more.
2.3. Data collection
Data extraction of the selected studies was independently
completed by two investigators using an agreed coding protocol
(available upon request). The authors of three studies were
contacted to request additional information. A response was
obtained from a study pending publication, which was included in
the meta-analyses. The level of agreement between the coders was
high (average agreement percentage = 95.53; average Kappa = .91).
2.4. Outcome variables
The comparable measures reported by at least three studies
were considered as the minimum measures needed to successfully
perform a meta-analysis, finally resulting in four outcomes of
interest: remission, completed suicide, depression, and function-
ing.
As a measure of remission, the percentage of subjects who
achieved diagnostic remission for BPD at a specific follow-up point
was used; this measure differs from the cumulative remission rate,
which is defined as the percentage of subjects who achieved a
particular period of remission throughout the duration of the
follow-up. Completed suicide was computed as the number of
subjects who completed suicide during follow-up divided by the
total number of subjects included at baseline in the respective
study.
Depression and functioning were studied through the means of
diverse instruments used in the studies. Their comparability was
determined by consensus of the authors.
2.5. Definition of moderators
The potential factors reported by at least three studies were
considered as moderators; age at baseline, gender, time of follow-
up, comorbidity with mood disorders at baseline, initial level of
functioning, presence and type of controlled treatment and its
length in months, and total hours of therapy were studied.
As a measure of the initial level of functioning, we converted the
mean scores of the functioning scales at baseline into a z-score,
comparing the mean values in each study with those reported for
these instruments in clinical populations from the corresponding
countries, which mainly consisted of outpatients with anxiety or
affective disorders [25,26,27,28,29,30].
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controlled treatment at the outset of the follow-up, comparing
samples of naturalistic studies with those of follow-up clinical
trials. Any treatment received in experimental conditions (e.g.,
predetermined prescription or length of treatment, attendance
monitoring, etc.) was considered as a controlled treatment.
Secondly, we compared those subgroups receiving specialised
therapy for BPD or other personality disorders with those receiving
TAU in follow-up clinical studies. Finally, we studied the length of
the controlled treatment in these subgroups and, where possible,
the total hours of formal therapy received, including both
individual and group modalities. To this end, we calculated the
total amount of hours of formal therapy, multiplying the number of
therapy sessions by the hours per session.
2.6. Quality assessment
A quality assessment of studies was performed with the SAQOR,
which was developed to assess quality in psychiatric research [31].
We followed the adapted guidelines used to assess both interven-
tion and longitudinal studies in a former meta-analysis [32].
According to the purpose of the present review, quality was
assessed considering the presence of BPD diagnosis as the
exposure variable, regardless of the original design or aims of
the studies. Gender/age, psychiatric comorbidity, type of initial
treatment, amount of therapy during the follow-up, and other
variables were considered among factors that might affect the
association between BPD diagnosis and the long-term outcome.
The control group domain was not applied, since the results of
these samples were not analysed. The final SAQOR ratings were
modified to maintain a similar sensitivity of the scale (see Table 1).
Two of the authors completed the ratings, with an 89% average
interrater agreement in domains’ scores (average Kappa = .78) and
an 82% in final ratings (Kappa = .63).
2.7. Meta-analyses
2.7.1. Effect size computation
For remission and completed suicide, the event rate itself was
treated as a measure of effect size; event rates were converted into
percentages. In the study of depression and functioning, the effect
size used was Hedges’ unbiased g standardised mean difference
and was calculated by subtracting the mean scores at baseline from
the mean at the follow-up, divided by the standard deviation
within groups [33]. Since test-retest information is used to adjust
the standard errors of the effect size estimates, we used test-retest
correlation coefficients of 0.50, .60 and, .70 (presented here are
those results based on a correlation of .50; the remaining analyses
may be obtained upon request, but no substantial differences were
found). Hedges’ g was computed in such a way that positive values
indicate more of a particular outcome (i.e., more depression and
more functioning).
2.7.2. Meta-analytic procedures
We ran four separate meta-analyses, one for each outcome
variable of interest (i.e., remission, completed suicide, depression,
and functioning). The likelihood of publication bias was tested
using the Egger’s regression test [34] in those meta-analyses with
at least ten of the studies (i.e., remission and suicide) and the trim-
and-fill procedure [35] in the remaining number [36].
To determine whether each set of independent estimates
shared a common effect size, we computed the homogeneity Q
statistic and the I2 index (i.e., the estimated percentage of the total
amount of variability that can be attributed to heterogeneity)
[37,38]. Since heterogeneity was observed in three of the four
meta-analyses, effect sizes were combined under the random-effects model using the restricted maximum-likelihood estimation
to estimate the amount of heterogeneity [39]. We obtained an
estimate of the overall effect size (i.e., event rate or Hedges’ g) for
each outcome of interest, which was also tested by computing a
95% confidence interval (CI) and the associated p value.
To examine the relationship between the moderators and the
effect sizes, a mixed-effects model was used (i.e., random-effects
model with moderators), using restricted maximum-likelihood to
estimate residual heterogeneity. For quantitative moderators, we
report the estimated parameter, its 95% CI, the QM (i.e.,
heterogeneity accounted for by the moderator), and the associated
p value. For categorical variables, we report the estimated effect
sizes within each level of a moderator with the corresponding 95%
CI, and the QB and its statistical significance. Analyses were
conducted with the Comprehensive Meta-Analysis (CMA) soft-
ware [40].
3. Results
3.1. Description of studies
A total of 1718 records were identified through database
searching and other sources. Fig. 1 describes the flow chart of the
selection process. After removing duplicates, 769 records were
screened that fulfilled inclusion criteria. Reasons for exclusion
were: the design of the study was not prospective, the absence of a
specified BPD sample, the lack of repeated outcome measures, and
a follow-up period that did not course entirely through adulthood
or was shorter than five years. Finally, twenty full-text articles
corresponding to eleven prospective studies were selected and
included in at least a meta-analysis.
Table 1 describes the studies included in the meta-analyses
and the outcome variables which were analysed from each of
them. There were five clinical trials with long-term post-
treatment follow-ups and six naturalistic studies without a
controlled treatment phase. The methodological qualities of the
studies are displayed in Table 1. The time from baseline to
follow-up ranged from five to fourteen years, with a median
value of six years. Overall, 837 participants from nine countries
completed both assessments. The majority of studies showed a
retention rate of more than 60 percent, with the exception of the
naturalistic study with a fourteen-year follow-up [13]. Mean
ages at baseline oscillated between 27 and 35 years, and the
percentages of women were between 47% and 100%. Percentages
of comorbidity with mood disorders at baseline fluctuated
between 37.7% and 100%; this last percentage was due to one
study conducted in a sample of primary care patients diagnosed
with both major depressive disorder and BPD [12]. Recruitment
settings in the rest of studies were outpatient or inpatient
psychiatric services.
3.1.1. Measures of outcome
Selected studies reported follow-up data in several areas, i.e.,
the presence of BPD diagnosis and BPD symptomatic domains,
dimensional personality traits, Axis II and Axis I comorbidity,
general psychopathology, depression, anxiety, interpersonal prob-
lems, suicidal behaviour, psychosocial and global functioning, and
quality of life. We only found comparable data for the four
outcomes analysed (see Table 1).
Regarding remission, the CLPS was excluded from the meta-
analysis due to its reporting of cumulative remission rates [9].
Aside from this type of measure, the MSAD also reported a specific
remission rate at a six-year follow-up that was considered in the
analyses [49]. The presence/absence of BPD diagnosis was
generally assessed by similar instruments at baseline and
follow-up, with the exception of two studies [13,20].
Table 1
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Note. CT = Controlled Treatment; TAU = Treatment as usual; DIB = Diagnostic Interview for Borderline Patients; DIB-R = Revised Diagnostic Interview for Borderlines; DIBD-
R = Diagnostic Interview for DSM-III-R Personality Disorders; DIPD-IV = Diagnostic interview for DSM-IV Personality Disorders; DIP-I = DSM-IV and ICD-10 Personality
Disorders Interview; SCID = Structured Clinical Interview for DSM-III-R; SCID-II = Structured Clinical Interview for DSM-IV-Axis II; ZAN-BPD = Zanarini Rating Scale for
Borderline Personality Disorder; IPDE = International Personality Disorder Examination; BDI = Beck Depression Inventory; BDI-II = Beck Depression Inventory-II; 17-
HDRS = 17-item Hamilton Depression Rating Scale; SFQ = Social Functioning Questionnaire; GAF = Global Assessment of Functioning; WSAS = Work and Social Adjustment
Scale; SOFAS = Social and Occupational Functioning Assessment Scale; SASS = Social Adaptation Self-evaluation Scale. a SAQOR ratings: High = 5-4 Adequate domains;
Moderate = 3-2 Adequate domains; Low  1 Adequate domain; bWaiting list control group was present in the original trial, although follow-up data was not reported for this
group; c n = 15 for remission outcome variable; d Initial n used to intent-to-treat analyses for depression,n at follow-up used for remission; eIntent-to-treat sample; f GAF
scores only reported at baseline in these studies.
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Inventory (BDI or BDI-II) and the 17-item Hamilton Rating Scale for
Depression (HRSD-17). The Dysphoric Affect Scale (DAS) was used
by the MSAD and was not considered comparable to the BDI/BDI-II
and HRSD-17 due to the fact that this instrument identifies other
dysphoric states apart from depression [51].
A variety of instruments were used as a measure of functioning,
including (a) scales rated by clinicians: the Global Assessment of
Functioning (GAF) and the Social and Occupational Functioning
Assessment Scale (SOFAS), and (b) self-report questionnaires: the
Social Functioning Questionnaire (SFQ), the Work and SocialAdjustment Scale (WSAS), and the Social Adjustment Scale-Self-
Report (SASS). Results on GAF scores were partially reported by
three studies and were not analysed [9,20,49]. Besides, the MSAD
was also excluded due to reporting specific indexes of psychosocial
functioning [8,52].
3.1.2. Treatment interventions
Table 2 illustrates the controlled treatment conditions com-
pared in the follow-up clinical trials included in the meta-analyses.
Controlled treatments lasted for one to three years and were
mainly conducted in outpatient settings, with the exception of two
Fig. 1. Flow chart of selection process.
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treatment [19,20]. The hours of formal therapy fluctuated between
60 and over 600 h, the latter reported by the MBT trial [20].
Among naturalistic studies, two studies followedup sampleswho
initially participated in a clinical trial, although treatment subgroups
were not individually studied at follow-up [10,13]. Besides, three
naturalistic studies informed of treatment use during follow-up in
general terms. The CLPS and MSAD studies reported similar
percentages of subjects in BPD samples who participated in
individual therapy during the early years of follow-up, which tended
to decrease over time (range, 85%-64% and 96%-75%, respectively)
[53,54]. Álvarez-Tomás et al. also reported that 75% of subjects
received individual therapy over the 10-year period [10].
3.2. Meta-analytic results
There was no evidence for publication biases with respect to the
four outcome measures studied in meta-analyses, according to the
results of the Eggers regression test (Remission, t = 0.41, df = 10, p =
.69; Completed suicide, t = 1.98, df = 8, p = .08) and the trim and fill
method (no study trimmed for depression and functioning).
3.2.1. Remission
Nine studies were analysed for remission, corresponding to
twelve comparisons. The mean remission rate was 60% (49–71, 95%
IC), although remission rates showed high heterogeneity among
studies (Q = 57.9, p < .001; I2 = 80.9%). The percentages of remission
in each study are displayed in Table 1.
The results of the effects of moderatorsare summarised inTable 3.
Groups with a younger mean age at baseline were more likely to
show higher remission rates at follow-up (QM= 4.48, p = .03). Greater
percentages of women in the samples were associated with higherremission rates in the long-term, although this tendency did not
reach statistical significance (QM = 2.98, p = .08). Time of follow-up,
percentage of comorbidity with mood disorders at baseline, and
initial level of functioning did not demonstrate a significant
influence on long-term remission. No significant differences in
mean remission rates were observed between groups receiving and
not receiving an initial controlled treatment, i.e., clinical trials vs
naturalistic studies (61% vs. 59%). Among clinical trials, the mean
remission rate in groups receiving a specialised therapy was higher
than in those receiving TAU (70% vs. 52%), although this difference
was not statistically significant. No relevant impact of the length of
treatment or the hours of formal therapy received was found.
3.2.2. Completed suicide
Seven studies were considered for completed suicide, which
represented ten comparisons. The mean suicide rate was 4% (2–5,
95% CI); the values were homogeneous among studies (Q = 8.68, p =
.47; I2 = .0%). The percentages of completed suicide in the studies
ranged from 0% to 8%, as shown in Table 1. Due to the low
heterogeneity presented among studies, the effects of moderators
were not studied on this outcome variable.
3.2.3. Depression
Four studies were studied for depression, comprising six
comparisons. Meta-analytic results showed a significant reduction
in depressive symptoms at follow-up, indicated by a medium mean
effect size (g = -0.70, [-1.04, -0.36] 95% CI, p < .001). However, there
was high heterogeneity among the studies (Q = 23.40, p < .001;
I2 = 78.6%).
The percentage of comorbidity with mood disorders at baseline
was not studied as a moderator on depression because there were
no data from at least three studies. No relevant impact of
Table 2
Description of controlled treatment conditions in follow-up clinical studies.
Study Type of Treatment Treatment
Setting
Description of Treatment conditions Hours therapy
(Months)
(1) Stevenson & Meares, 1992
Stevenson et al., 2005 [23,41]
Conversational Therapy
(ST)
Outpatient 2 sessions/week, 1 h session duration. Manualised Psychodynamic-
Interpersonal Psychotherapy.
Optional inpatient stays when in crisis. Optional medication use.
Therapists: 17 psychiatrists, 2 psychiatric nurses, 1 psychologist.
Weekly supervision by audiotapes of sessions
96
(12)








DH: 18 months, 1 session/week psychoanalytic IT, 3 sessions/week
analytic GT (1 h each), 1/week psychodrama GT (1 h), 1/week
community meeting GT (1 h). Average length = 1.45y, 62% attendance at




OT: 18 months 2 sessions/week analytic GT (180 hours over 18 months).
75% attendance at group therapy sessions. Medication and every 3
months psychiatric consultations. Optional inpatient stays when in
crisis.
Manualised psychotherapy. Therapists: nurses. 2/week Supervision.
TAU Outpatient 18 months: No formal psychotherapy. 2/month individual community
support by mental health nurses, 100% attendance. Medication and 2/
month psychiatric consultations on average. Optional psychiatric DH
(admission rate = 72%, average length stay = 6 months). Optional
inpatient stays when in crisis.
–
(36)
18 months: Medication and psychiatric consultations, community
support IT. Optional inpatient stays or psychiatric DH when in crisis.
Psychotherapy but not MBT IT when recommended.
(3) Davidson et al., 2010
Davidson, Norrie et al., 2006




Outpatient CBT-PD: 12 months, 30 IT sessions, 1 h duration. CBT for Cluster B PDs.
Manualised Psychotherapy. Trained therapists and weekly supervision.
TAU: Idem as comparison group.
16
(12)
TAU Outpatient Minimum Treatment: OT General practitioner care + Community
mental health teams (CMH, 90% total sample). Optional psychological
intervention when in crisis. Optional Accident and Emergency (A&E)
visits when self-harm episodes (50% total sample) and inpatient stays
when in crisis. Optional occupational and social attendance.
–
(12)
(4) Antonsen et al., 2017






DH: 18 weeks, 3-4 days/week, psychodynamic GT, schema focused
cognitive GT, anxiety cognitive behavioural GT
OT combined psychotherapy: max 4y, weekly 1.5-h sessions GT, max
2.5y, weekly IT. Written manual. Relational psychotherapy, group






Outpatient No manual. No specific psychotherapeutic model, duration or intensity
of treatment.
Optional psychopharmacological consultations by psychiatrist.
60
(24)
(5) Sahin et al., 2017 [22] Object-relational
Psychotherapy (ST 1)
Outpatient 2 sessions/week IT. Manualised psychotherapy. Trained therapists and
supervision.





Outpatient 1 session/week IT, weekly 2 h sessions GT. Optional phone calls with
therapists between sessions. Manualised psychotherapy. Trained
therapists and supervision.
Continuity of treatment after experimental phase was optional.
144
(12)
TAU Outpatient Usual treatment in psychiatric units –
(12)
Note. ST = Specialised Therapy; TAU = Treatment as usual; CBT-PD = Cognitive Behavioural Therapy – Personality Disorders; OIP = Outpatient Individual Therapy; DH = Day
Hospital; OT = Outpatient Treatment; GT = Group Therapy; IT = Individual Therapy. Community support by health professionals was not considered as formal therapy. When
duration of sessions was not informed, it was computed 1 h per session. Real over planned data on use of therapy was preferred for calculations.
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treatment. Longer treatments were associated with increased
improvement in depression over time, although this trend did not
reach statistical significance (QM = 3.01, p = .08).
3.2.4. Functioning
Five studies were synthesised for functioning, which repre-
sented nine comparisons. A significant improvement in long-term
functioning was also found, with a medium mean effect size (g =
0.66, [0.43, 0.89] 95% IC, p < .001). However, there was high
heterogeneity among studies (Q = 25.54, p = .001; I2 = 68.7%).
Groups with a higher percentage of women were more likely to
present lower improvement in functioning at follow-up (QM= 7.24, p =
.007); age at baseline, time of follow-up, and initial level of
functioning showed no relevant impact on long-term functioning.
The initial rate of comorbidity with mood disorders was also notstudied for functioning because there were no data from at least
three studies. Differences in functional improvement between
groups from naturalistic studies and those from clinical trials
receiving a controlled treatment were not significant, although the
latter showed a greater estimated effect size (g = 0.43 vs. g = 0.74, p =
.11). In clinical trials, receiving specialised therapies or TAU did not
show a relevant impact on functional change. There was a non-
significant relationship between longer treatments and higher
functional improvement (QM = 3.16, p = .07), whereas the hours of
formal therapy received did not have a relevant influence on
functioning.
4. Discussion
This meta-analytic study synthesised current findings from
prospective research on the long-term course of BPD in adulthood.
Table 3
Results of the effects of moderators on remission, depression, and functioning.
Remission Depression Functioning
Moderators Estimate [95% CI] QM (df) p Estimate [95% CI] QM (df) p Estimate [95% CI] QM (df) p
Mean Age 0.13 [-0.25,-0.01] 4.48 (1) .03 0.05 [-0.01, 0.12] 2.72 (1) .10 0.02 [-0.04, 0.08] 0.41 (1) .52
% Women 0.03 [-0.00, 0.06] 2.98 (1) .08 0.01 [-0.07, 0.10] 0.13 (1) .72 0.03 [-0.05, -0.01] 7.24 (1) .01
Time of Follow-up 0.11 [-0.08, 0.30] 1.23 (1) .27 0.07 [-0.25, 0.11] 0.52 (1) .47 0.09 [-0.23, 0.05] 1.68 (1) .19
% Mood Disorders 0.01 [-0.07, 0.09] 0.04 (1) .84 — — — — — — — — — —
Mean Initial Level of Functioning (z score) 0.61 [-0.32, 1.54] 1.67 (1) .20 0.18 [-0.28, 0.65] 0.60 (1) .44 0.00 [-0.38, 0.37] 0.00 (1) .98
Length of Treatment 0.02 [-0.06, 0.12] 0.33 (1) .57 0.04 [-0.01, 0.08] 3.01 (1) .08 0.03 [-0.00, 0.07] 3.16 (1) .07
Hours of Formal Therapy 0.00 [-0.00, 0.01] 1.02 (1) .31 0.00 [-0.01, 0.01] 0.15 (1) .70 0.00 [-0.01, 0.00] 1.13 (1) .29
Rate [95% CI] QB (df) p g [95% CI] QB (df) p g [95% CI] QB (df) p
Presence of Controlled Treatment 0.03 (1) .85 0.22 (1) .64 2.50 (1) .11
No Controlled Treatment 59% [.42, .74] 0.58 [-1.21, -0.06] 0.43 [0.17, 0.69]
Controlled Treatment 61% [.45, .76] 0.77 [-1.23, -0.30] 0.74 [0.45, 1.03]
Type of Controlled Treatment 0.57 (1) .45 0.52 (1) .47 0.08 (1) .77
Specialised Therapy 70% [.41, .89] 0.95 [-1.68, -0.23] 0.79 [0.26, 1.31]
TAU 52% [.20, .83] 0.58 [-1.30, 0.15] 0.70 [0.47, 0.93]
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and 70% of patients diagnosed with BPD may achieve symptomatic
remission at some point between five and fifteen years of follow-
up; this finding is consistent with former literature indicating that
BPD diagnosis leans towards increasing proportions of remission
over time. The Montreal study retrospectively reported that 75% of
patients with BPD achieved remission at fifteen years and over 90%
did so at 27 years of follow-up [2]. Both the MSAD and CLPS studies
also provided evidence for an enduring symptomatic remission of
BPD, despite reporting cumulative rates of remission [6]. To our
knowledge, our study is the first meta-analysis reporting
estimated remission rates prospectively assessed at a specific
point, which may be useful in comparing the long-term effects of
treatments for BPD patients over the course of the disorder.
Notably, depressive symptomatology and functioning in
patients with BPD also lean towards improvement in the long-
term. Findings are consistent with those reported by the CLPS and
MSAD studies, indicating that the psychosocial functioning of BPD
subjects may vary among individuals, but show a significant
improvement over time as a group [6]. However, our results do not
allow one to conclude whether individuals with BPD can reach
normative functional adjustment in the long-term, although
previous research indicates that a relevant proportion may suffer
from persistent impairments over time [8,9,10,13,52]. In terms of
depressive symptoms, the MSAD study also reported a significant
decrease in dysphoric states in the long-term, which was more
pronounced in recovered patients [51]. Despite this favourable
outcome in clinical and functional realms, we found that the rate of
completed suicide in BPD subjects might be expected to be
between 2% and 5% during the second half of the decade of follow-
up; percentages were lower than those based on previous follow-
back research at fifteen and 27 years, which were between 8% and
10%. This fact is consistent with the hypothesis that completions
are more likely to occur later in the course of the illness [1,2].
We further investigated potential moderators for those out-
comes which presented high heterogeneity in the meta-analyses.
Regarding patients’ age at baseline, we found that a diagnosis of
BPD at a younger age was associated with higher percentages of
remission in the long-term, whereas this moderator did not
influence changes in depression and functioning. This is congruent
with previous evidence indicating that BPD symptom severity may
decline from adolescence to mid-adulthood, particularly in terms
of the externalising manifestations of the disorder (i.e., impulsivity
and suicidal behaviours) [55,56,57,58]. Younger age has also been
identified as a predictor of shorter time to remission [14]. In
contrast, the CLPS informed of similar rates of improvement in BPDsymptoms in younger and older subjects over six years of follow-
up [15]. This discrepancy in longitudinal findings suggests that
age-related divergences might also be influenced by the duration
of the illness, which is expected to be longer the older one becomes
but with variations among subjects. Similarly, it would be useful to
consider the age of onset and the duration of illness as specific
moderators when studying the course of the disorder. In terms of
functioning, cross-sectional research has reported, contrary to our
findings, greater functional impairments in older age, when it is
more likely to present worse physical health, poorer quality of life,
and greater social assistance utilisation [56,57,58]. Nevertheless,
this decline in functioning is more dramatically suffered in
advanced age, whereas subjects comprising the study samples
in our analysis were mostly in their 20 s and 30 s at baseline.
Consistent with this hypothesis, the CLPS study reported that older
participants only showed a higher decline in functioning midway
through the follow-up [15].
A striking finding was that female gender was associated with a
lower improvement in functioning, whereas there were no
significant differences in gender with regard to changes in BPD
diagnosis and depression in the long-term. These results are
consistent with those informed by the MSAD, which did not report
a significant impact of gender on time to remission over ten years
[14]. Unfortunately, there is scarce evidence on gender differences
regarding the functional course of BPD. In this respect, our findings
indicate that the long-term functional recovery in women with
BPD might be hampered by other causes apart from the persistence
of the disorder. A possible explanation is that psychopathological
divergences between genders in symptom severity and comorbid-
ity might deeply interfere with the long-term functional outcome
of BPD women, in spite of showing similar trends of clinical
improvement over time. In this line, there is evidence from cross-
sectional research on gender differences that female BPD subjects
present greater percentages of lifetime Axis I comorbidity and
higher severity in general psychopathology, particularly in areas
related to internalising patterns such as anxiety, depression, and
somatisation [59,60]. Additionally, BPD women are more likely to
have a history of childhood sexual abuse and experience episodes
of physical and sexual aggression during adulthood, which is
related to higher psychosocial impairment [59,61]. On the other
hand, sociological studies have noted that gender roles determine
different strains and benefits of normative social adaptation for
men and women, which might also contribute to hindering
psychosocial adjustment in female BPD subjects; for example,
caregiving roles for women in the general population are
associated with greater psychological distress and increased
82 I. Álvarez-Tomás et al. / European Psychiatry 56 (2019) 75–83reductions in the protective benefits of employment for mental
health, reporting higher rates of exposure to stressful life events
involving significant others [62,63].
Receiving an initial controlled treatment does not seem to
increase the amount of clinical improvement in the long-term
compared to the course of the disorder described in naturalistic
studies. Besides, both specialised therapies and TAU seem to
similarly improve the long-term clinical outcome, despite observ-
ing non-significant differences in mean remission rates between
those groups. This contrasts with previous research indicating a
higher efficacy of specialised therapies for BPD in the short-term
[64,65], which suggests that the differential effects of psychother-
apeutic interventions might be diluted by the diverse mechanisms
of change over the lifespan. On the other hand, the long-term
functioning of BPD patients appears to be enhanced by any kind of
controlled treatment, particularly those that are implemented over
a longer period of time, although these trends did not reach
statistical significance in our analyses. This might indicate that
common components of psychotherapies are key factors in
promoting changes in psychosocial functioning in the long-term
[66]. One aspect to note is that the methodological limitations of
the selected studies may affect these results on treatment
moderators. First, other confounding factors are likely to interfere
with treatment efficacy in long-lasting post-treatment follow-ups,
including the likelihood of receiving further treatment after the
experimental phase. Secondly, most BPD subjects in naturalistic
studies might also have received some form of uncontrolled
treatment during the follow-up period [2,64].
The length of follow-up was not relevant to explain the
variations in the outcomes, suggesting a low pace of change in the
long-term. This differs from the early years of illness when more
dramatic shifts in BPD symptoms may occur [1,14]. Additionally, no
significant effects of the initial level of functioning and the
percentage of comorbid mood disorders were found; this contrasts
with findings from the CLPS indicating that a comorbid major
depressive disorder is associated with a delayed time to remission
from BPD, likely due to differences in the operationalisation of
remission in this study [16].
There are strengths and limitations of this meta-analysis to
consider. We included follow-along studies conducted in a variety
of clinical settings and countries, which increases the generalisa-
tion of the findings. We also analysed the impact of several factors
on the heterogeneity of the outcomes; however, the majority of
selected studies reported results at follow-up lasting between five
and ten years, largely restricting the scope of our findings to this
time period. In general, the scarcity of selected studies and the
small size of the BPD samples in most of them reduced the
statistical power of the analyses and therefore may have affected
the study of the effects of moderators. Additionally, the lack of data
or the variability of measures used among studies restricted the
analysis of other potential moderators and outcomes. Finally, we
studied correlational relationships between moderators and long-
term outcomes and, therefore, we cannot establish causal links
based on our findings.
5. Conclusion
Our findings confirm a pattern of clinical and functional
improvement over time in patients diagnosed with BPD. It is
tempting to think about the beneficial effects of psychotherapeutic
interventions, specialised or not, on the functional long-term
course, but further research on the long-term effects of psycho-
therapies is required to reach consistent conclusions in this regard.
Moreover, longitudinal studies in untreated samples might also
enrich our knowledge of the natural course of BPD and the study of
treatment efficacy. In general, the consistent use of clinical andfunctional measures for BPD would facilitate meta-analytic
research in this field.
Our results lead to the conclusion that BPD diagnosis at a younger
age corresponds to a better clinical prognosis in the long-term,
whereas similar rates of functional improvement are achieved byage
over time. This justifies direct efforts towards the early detection of
BPD, allowing the implementation of effective treatments during
patients’ youth to reduce the adverse effects of the disorder during
this critical life stage. In addition, functional improvement in the
long-term is hampered in women with BPD; accordingly, it is
essential to incorporate a genderperspective to address psychosocial
interventions for these patients, particularly due to the higher
percentage of women amongtreatment-seekers with BPD diagnosis.
Moreover, the use of study designs that allow gender comparisons
would be recommended.
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